Taysha Gene Therapies Inc (TSHA)
1.265
-0.08
(-5.60%)
USD |
NASDAQ |
Nov 05, 14:55
Taysha Gene Therapies Total Liabilities (Quarterly): 91.52M for June 30, 2024
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 91.52M |
| March 31, 2024 | 99.15M |
| December 31, 2023 | 97.79M |
| September 30, 2023 | 244.88M |
| June 30, 2023 | 118.66M |
| March 31, 2023 | 116.55M |
| December 31, 2022 | 125.33M |
| September 30, 2022 | 100.34M |
| June 30, 2022 | 109.62M |
| Date | Value |
|---|---|
| March 31, 2022 | 115.25M |
| December 31, 2021 | 118.57M |
| September 30, 2021 | 100.65M |
| June 30, 2021 | 55.36M |
| March 31, 2021 | 19.96M |
| December 31, 2020 | 7.579M |
| September 30, 2020 | 11.62M |
| June 30, 2020 | 20.09M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
7.579M
Minimum
Dec 2020
244.88M
Maximum
Sep 2023
91.35M
Average
100.34M
Median
Sep 2022
Total Liabilities (Quarterly) Benchmarks
| CEL-SCI Corp | 15.60M |
| AIM ImmunoTech Inc | 9.613M |
| IGC Pharma Inc | 2.714M |
| NovaBay Pharmaceuticals Inc | 4.542M |
| Protalix BioTherapeutics Inc | 62.96M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 200.39M |
| Shareholders Equity (Quarterly) | 108.87M |
| Debt to Equity Ratio | 0.3475 |
| Current Ratio | 5.222 |
| Net Debt Paydown Yield | 0.01% |